tbuckley/cabot-search huggingface dataset:
AB0561 AUTOMATIC QUANTIFICATION OF INTERSTITIAL LUNG DISEASE FROM CHEST COMPUTED TOMOGRAPHY IN SYSTEMIC SCLERODERMA
Authors: A. Carvalho, A. Guimarães, F. R. Sztajnbok, R. Rodrigues, B. Silva, A. Lopes, I. Almeida, M. França
Journal: Annals of the Rheumatic Diseases (2020)

Background: Scleroderma-associated interstitial lung disease (SSc-ILD) is often observed in patients with systemic scleroderma (SSc) and its diagnosis contributes to early treatment decisions 1,2 . Objectives: The present study aims to automatically quantify SSc-ILD from high-resolution chest-computed tomography (HRCT) and to evaluate the association between interstitial lung disease (ILD) extension and lung function impairment. Methods: Ninety-four patients with SSc and 27 lung-healthy subjects matched for gender, weight, height, and age underwent HRCT, spirometry and carbon monoxide diffusion capacity (DL CO ). SSc-ILD was determined as the tissue mass present between -500 and +100 Hounsfield Units normalized by the total lung tissue mass (TLM). Cut off was the highest value obtained in the control group (25% of TLM). All data are presented as mean and standard deviations (Table I). An ANOVA test followed by Bonferroni post-hoc correction was used for comparisons among groups. Results: From 94 patients with SSc, 64 were classified as having pulmonary involvement (SSc-ILD) and 30 as not having pulmonary involvement (SSc No-ILD). In SSc-ILD subjects, there was a significant reduction in forced vital capacity (FVC), carbon monoxide diffusion capacity (DL CO ) and carbon monoxide diffusion capacity normalized by alveolar ventilation (DL CO /A) when compared with SSc No-ILD and control group. Conclusion: The proposed method allows the automatic quantification of SSc-ILD from HRCT and ILD extent is associated with pulmonary function impairment. References: [1]Doyle TJ, Dellaripa PF. Lung Manifestations in the Rheumatic Diseases. CHEST. 2017 Dec;152(6):1283–95. [2]Saketkoo LA, Magnus JH, Doyle MK. The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope. The American Journal of the Medical Sciences. 2014 Jan;347(1):54–63. Table 1. Demographic variables, pulmonary function tests and densitovolumetry considering scleroderma patients with less or greater pulmonary involvement. Control Group N = 27 SSc No-ILD N = 30 SSc-ILD N = 64 p-value Demographic Data Females 16 (59.2) 28 (93.3) 58 (90.1) - Age (years) 37.9 ± 14.8 51.2 ± 12.2 56 ± 14 &lt;0.011 a,b BMI (kg/m 2 ) 26.7 ± 5.1 24.1 ± 5.0 25.9 ± 5.7 - Lung Function FVC (% predicted) 100.2 ± 9.2 99.9 ± 19.8 69.8 ± 16.7 &lt;0.001 b,c DLco (% predicted) 103 ± 13.3 83.8 ± 14.2 63.4 ± 20.3 &lt;0.002 a,b,c DLco/A (% predicted) 112.7 ± 17.4 85.7 ± 12.9 79.2 ± 20.6 &lt;0.001 a,b Densitovolumetry TLV mL 4675 ± 986 4471 ± 916 3492 ± 1120 &lt;0.001 b,c Lung Tissue Mass (g) 793 ± 125 756 ± 159 731 ± 155 - ILD Extent (% LTM) 17 ± 2 22.9 ± 1.2 32.6 ± 8 &lt;0.003 a,b,c a: Statistically significant difference between No-ILD SSc and control group; b and c: Statistically significant difference between SSc-ILD vs control group and SSc No-ILD, respectively. Disclosure of Interests: None declared
Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Shaji K. Kumar, Magdalini Migkou, Manisha Bhutani, Andrew Spencer, Sikander Ailawadhi, Anna Kalff, Farzana Walcott, Nabendu Pore, Diana Gibson, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yu Jiang, Jeffrey Zonder, Jeremy Larsen, Shreerang Sirdesai, Andrew J. Yee, Meletios A Dimopoulos
Journal: Blood (2020)
Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era
Authors: Dawn Maze, Murat O. Arcasoy, Ryan Henrie, Sonia Cerquozzi, Rammurti Kamble, Samer Al Hadidi, Abdulraheem Yacoub, Mahmoud Elsawy, Shireen Sirhan, Anurag K. Singh, Elliot Smith, Curtis Marcoux, Dietrich Werner, Wenda Greer, Auro Viswabandya, Andrew Daly, Hassan Sibai, Caroline J McNamara, Wei Xu, Katherine Lajkosz, Lynda Foltz, Vikas Gupta
Journal: Blood (2020)
Abstract 13176: Beneficial Effects of Purified Eicosapentaenoic Acid on Myocardial Fibrosis and Diastolic Cardiac Function in Spontaneously Hypertensive Rats
Authors: Adam W Pflum, Killian C Robinson, Jianli Bi, Vivian Xu, David M Herrington, Giselle C Meléndez
Journal: Circulation (2018)

Introduction: Hypertensive patients often experience left ventricular (LV) dysfunction associated with cardiac fibrosis. Pre-treatment with eicosapentaenoic acid (EPA) prevent these deleterious eff...
Detection of Systemic AL Amyloidosis and Differentiation of AL from Attr Using 124I-p5+14 PET Imaging
Authors: Jonathan S. Wall, R. Eric Heidel, Alan Stuckey, Emily B. Martin, Tina Richey, Angela Williams, James S. Foster, Bryan Whittle, Yitong Fu, Dustin Powell, Ronald H. Lands, Spencer Guthrie, Stephen J. Kennel
Journal: Blood (2020)
Transfusion Requirements in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria with or without a History of Bone Marrow Disorder Receiving Ravulizumab and Eculizumab: Results from a Phase 3 Non-Inferiority Study Extension
Authors: Antonio Risitano, Jun-Ho Jang, Lee Gyeong-Won, Wanchai Wanachiwanawin, Hubert Schrezenmeier, Yuji Yonemura, Talha Munir, Rodrigo Pavani, Jimmy Wang, Alexander D. Kulagin, Austin Kulasekararaj, Flore Sicre de Fontbrune, Alexander Röth
Journal: Blood (2020)
Continuous Clinical Remisssion with High MRD Negativity and High PB and BM MRD Concordance during Venetoclax Monotherapy in R/R CLL Patients
Authors: Maria Dimou, Ioannis Anagnostopoulos, Sotiria Kalyva, Vasileios Pardalis, Athanasios Markopoulos, Aikaterini Bitsasni, Theodoros Iliakis, Marie-Christine Kyrtsonis, Panayiotis Panayiotidis
Journal: Blood (2020)
Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature That Predicts Relapse Risk and Survival Probability in Multiple Myeloma
Authors: Ehsan Malek, E. Ricky Chan, Daniel Qu, Jane Reese, Robert Fox, Byung-Gyu Kim, Paolo F Caimi, Marcos de Lima, James J. Driscoll
Journal: Blood (2020)
Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate
Authors: Jennifer N Saultz, Kaycee Moshofsky, Andy Kaempf, Guang Fan, Gabrielle Meyers, Rachel J. Cook, Richard T. Maziarz, Peggy Appel, Francisco Tria, Staci Williamson
Journal: Blood (2020)
Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma
Authors: Eric M. Ammann, Annette Lam, Wenze Tang, Tobias Kampfenkel, Mohit Sharma, Charlene Lee, Shuchita Kaila, Alex Z. Fu, Kathleen Gray, Jianming He
Journal: Blood (2020)
AB0979 MEVALONATE KINASE DEFICIENCY AT TREATMENT WITH CANAKINUMAB: RARE BELATED CUTANEOUS FEATURE
Authors: R. Dos Santos Sobrín, B. Lopez-Montesinos, M. Martí Masanet, L. Lacruz Pérez, I. Calvo
Journal: Annals of the Rheumatic Diseases (2020)

Background: Mevalonate Kinase Deficiency (MKD) is an autosomal recessive autoinflammatory syndrome. Diagnostic criteria are based in clinical and genetic features (mutations in MVK gene) and its main treatment consists of blocking IL-1 1-5 . Objectives: To describe a case-series of a rare bleated cutaneous feature. Methods: From January 2004 to September 2019, all cases diagnosed of MKD have been reviewed. Results: 15 patients had MKD diagnosis (11 pathogenic mutations, homozygosis or double heterozygosis). Most common symptoms were oral and genital aphthous, abdominal pain, adenopathies and recurrent fever. Mean age of diagnosis was 10,67 years old (8,67 years later from the beginning of symptoms). Mean time of follow-up was 10 years. 3 patients developed this rare bleated cutaneous feature: suppurative hydrosadenitis. When the first injury appeared, all were at treatment with Canakinumab (mean time of treatment 4 years) and had 7,67 years of MKD course. This comorbidity began as repeating abscesses in folds with apocrine glands and hair follicles (armpits, inguinal, anal and genital folds). 2 patients continued Canakinumab and 1 switched to Adalimumab because of severity of cutaneous involvement. Conclusion: This is the first case-series showing suppurative hydrosadenitis associated to MKD that has not been described in literature. Both theories have been found: as immune-mediated disease partnering this autoinflammatory syndrome (MKD) or as adverse event of treatment (anti-IL-1, less presumable). References: [1]Van der Meer JW, Simon A. The challenge of autoinflammatory síndromes: with an emphasis on hyper-IgD syndrome. Rheumatology 2016;55:23-29. [2]Arnal C, Modesto C. Sídnromes febriles periódicos hereditarios: nuevas perspectivas sobre su conocimiento clínico y genético. 2003;30(2):45-48. [3]Mulders-Manders C, Simon A. Hyper-IgD syndrome/mevalonate kinase deficiency: what is knew? Semin Immunopathol 2015;37:371-376. [4]Cush, J. Autoinflammatory Syndromes. Dermatol Clin 2013;31(3):471-480. [5]Moreira A, Torres B, Peruzzo J, et al. Skin symptoms as diagnostic clue for autoinflammatory diseases. An Bras Dermatol 2017;92(1):72-80. Disclosure of Interests: Raquel Dos Santos Sobrín: None declared, B Lopez-Montesinos: None declared, Miguel Martí Masanet: None declared, Lucía Lacruz Pérez: None declared, Inmaculada Calvo Grant/research support from: Bristol-Myers Squibb, Clementia, GlaxoSmithKline, Hoffman-La Roche, Merck Sharpe &amp; Dohme, Novartis, Pfizer, Sanofi, Speakers bureau: AbbVie, GlaxoSmithKline, Hoffman-La Roche, Novartis
Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results
Authors: Roberto Cairoli, Mauro Krampera, Patrizia Zappasodi, Elisabetta Todisco, Erika Borlenghi, Alfredo Molteni, Monica Fumagalli, Marta Ubezio, Massimo Bernardi, Rosa Greco, Erika Ravelli, Valentina Mancini, Giovanni Grillo, Marta Riva, Beatrice De Marco, Adriana Cassaro, Bruno Brando, Arianna Gatti, Silvio Marco Veronese, Alessandro Beghini
Journal: Blood (2020)
The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI
Authors: Anna Petrova, Ekaterina Yu. Chelysheva, Oleg A. Shukhov, Anastasiya Bykova, Irina Nemchenko, Olga Pospelova, Margarita Gurianova, Nikolay Tsyba, Tatiana I. Ionova, Anna G. Turkina
Journal: Blood (2020)
Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis
Authors: Idris Boudhabhay, Victoria Poillerat, Anne Grunenwald, Carine Torset, Juliette Leon, Marie V. Daugan, Francesca Lucibello, Khalil El Karoui, Amandine Ydee, Sophie Chauvet, Patrick Girardie, Steven Sacks, Conrad A. Farrar, Peter Garred, Romain Berthaud, Moglie Le Quintrec, Marion Rabant, Pascale de Lonlay, Caroline Rambaud, Viviane Gnemmi, Veronique Fremeaux-Bacchi, Marie Frimat, Lubka T. Roumenina
Journal: Kidney International (2020)
CircPlant: An Integrated Tool for circRNA Detection and Functional Prediction in Plants
Authors: Peijing Zhang, Yongjing Liu, Hongjun Chen, Xianwen Meng, Jitong Xue, Kunsong Chen, Ming Chen
Journal: Genomics Proteomics & Bioinformatics (2020)

Abstract The recent discovery of circular RNAs (circRNAs) and characterization of their functional roles have opened a new avenue for understanding the biology of genomes. circRNAs have been implicated to play important roles in a variety of biological processes, but their precise functions remain largely elusive. Currently, a few approaches are available for novel circRNA prediction, but almost all these methods are intended for animal genomes. Considering that the major differences between the organization of plant and mammal genomes cannot be neglected, a plant-specific method is needed to enhance the validity of plant circRNA identification. In this study, we present CircPlant, an integrated tool for the exploration of plant circRNAs, potentially acting as competing endogenous RNAs (ceRNAs), and their potential functions. With the incorporation of several unique plant-specific criteria, CircPlant can accurately detect plant circRNAs from high-throughput RNA-seq data. Based on comparison tests on simulated and real RNA-seq datasets from Arabidopsis thaliana and Oryza sativa, we show that CircPlant outperforms all evaluated competing tools in both accuracy and efficiency. CircPlant is freely available at http://bis.zju.edu.cn/circplant.
A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Paul G. Richardson, Akshanth R. Polepally, Monica Motwani, Yunming Mu, Zeena Salman, Sudhir Penugonda, Philippe Moreau
Journal: Blood (2020)
Use of Peripherally Inserted Central Catheter (PICC) for the Infusion of Peripheral Blood Stem Cell Products Is Safe and Effective
Authors: Shi Hui Clarice Choong, Michelle Poon, Teck Guan Soh, Jedidah Lieow, Lip Kun Tan, Liang Piu Koh, Wee-Joo Chng, Yee Mei Lee, Joanne Shu Xian Lee, Davanaliz Gonzales Ramos, Eng Soo Yap
Journal: Blood (2020)
First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network
Authors: Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, Arnaud Jaccard, Frank Bridoux, Wilfried Roeloffzen, M. Teresa Cibeira, Hermine Agis, Monique C. Minnema, Rui Bergantim, Roman Hajek, Cristina João, Ashutosh D. Wechalekar, Pieter Sonneveld, Efstathios Kastritis
Journal: Blood (2020)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
Authors: David P. Steensma, Pierre Fenaux, Koen Van Eygen, Azra Raza, Valeria Santini, Ulrich Germing, Patricia Font, Maria Diez-Campelo, Sylvain Thepot, Edo Vellenga, Mrinal M. Patnaik, Jun Ho Jang, Helen Varsos, Jacqueline Bussolari, Esther Rose, Laurie Sherman, Libo Sun, Ying Wan, Souria Dougherty, Fei Huang, Faye Feller, Aleksandra Rizo, Uwe Platzbecker
Journal: Journal of Clinical Oncology (2020)

PURPOSE Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC transfusion dependent and have experienced relapse after or are refractory to erythropoiesis-stimulating agent (ESA) have limited treatment options. High telomerase activity and human telomerase reverse-transcription expression in clonal hematopoietic cells have been reported in patients with MDS. Imetelstat, a first-in-class competitive inhibitor of telomerase enzymatic activity, targets cells with active telomerase. We report efficacy, safety, and biomarker data for patients with LR MDS who are RBC transfusion dependent and who were relapsed/refractory to ESAs. PATIENTS AND METHODS In this two-part phase II/III study (MDS3001), the primary end point was 8-week RBC transfusion independence (TI) rate, with key secondary end points of 24-week RBC TI rate, TI duration, and hematologic improvement-erythroid. RESULTS Data from the phase II part of the study are reported. Of 57 patients enrolled and treated (overall population), 38 were non-del(5q) and hypomethylating agent and lenalidomide naïve (subset population). The 8- and 24-week RBC TI rates in the overall population were 37% and 23%, respectively, with a median TI duration of 65 weeks. In the subset population, 8- and 24-week RBC TI rates were 42% and 29%, respectively, with a median TI duration of 86 weeks. Eight-week TI rate was observed across all subgroups evaluated. Cytogenetic and mutational data revealed a reduction of the malignant clones, suggesting disease modification activity. The most common adverse events were cytopenias, typically reversible within 4 weeks. CONCLUSION Imetelstat treatment results in a meaningful, durable TI rate across a broad range of heavily transfused patients with LR MDS who are ineligible for or relapsed/refractory to ESAs. Biomarker analyses indicated effects on the mutant malignant clone.
mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study.
Authors: Huabin Hu, Kun Wang, Wei Wang, Meng Qiu, Rongbo Lin, Haibo Zhang, GuangJian Liu, Yunle Wan, Liang Kang, Hui Wang, Zhiyang Zhou, Fangqian Li, Yan Huang, Jianwei Zhang, Yue Cai, Zehua Wu, Jiayu Ling, Meijin Huang, Yanhong Deng
Journal: Journal of Clinical Oncology (2020)

99 Background: Conversion therapy for unresectable colorectal liver metastases (LM) can downsize tumours and create a situation where the patient has no evidence of disease (NED). We assessed the effectiveness of cetuximab plus mFOLFOXIRI or mFOLFOXIRI in this setting. Methods: FOCULM was a prospective 2:1 controlled, multicenter, phase II trial. Given no free drugs offered and the patients' affordability for cetuximab, the study design has been amended from randomization to non-randomization since September, 2016. Patients with unresectable LM were assigned to receive cetuximab (500mg/m 2 ) plus mFOLFOXIRI (oxaliplatin 85 mg/m 2 , irinotecan 165 mg/m 2 , folinic acid 400 mg/m 2 , 5-fluorouracil 2800mg/m 2 46h infusion, every 2 weeks) (group A) or mFOLFOXIRI (group B). Primary endpoint was the rate of NED achieved, secondary endpoints were ORR, resection rate, the rate of local and ablative treatment (LAT), OS, PFS and DpR. Results: From February 2014 to July 2019, 114 patients were enrolled at 6 centers in China and 101 patients were in the ITT population (67 group A, 34 group B). Treatment groups were generally well balanced, although more patients with ≥5 LM were in group A. The rate of NED achieved was 62.7% in group A and 38.2% in group B (P = 0.020). At a median follow-up of 19.4 months, patients in group A had significantly prolonged the mOS, increased ORR, the rate of LAT and DpR compared with those in group B (Table). Patients with NED achieved yielded a significant survival benefit, whether in group A (Not reached vs. 49.4 months; P = 0.001) or group B (Not reached vs. 25.1 months; P = 0.007). Conclusions: The addition of cetuximab to a mFOLFOXIRI in patients with RAS/BRAF wild-type unresectable LM colorectal cancer significantly improved the rate of NED achieved, ORR and OS. Clinical trial information: NCT02063529. [Table: see text]
Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study
Authors: Dickran Kazandjian, Elizabeth Hill, Candis Morrison, Alexander Dew, Neha Korde, Sham Mailankody, Elisabet E. Manasanch, Mary L. Kwok, Manisha Bhutani, Nishant Tageja, Yong Zhang, Ashley Carpenter, Monica Epstein, Michael Emanuel, Crystal Lu, Raul C. Braylan, Katherine R. Calvo, Peter Choyke, Alina Dulau-Florea, Esther Mena, Liza Lindenberg, Irina Maric, Nisha Patel, Maryalice Stetler-Stevenson, Hao-Wei Wang, Constance M. Yuan, Seth M. Steinberg, William D. Figg, Mark Roschewski, Ola Landgren
Journal: Blood (2020)
Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant
Authors: Jianping Zhang, Junfang Yang, Xian Zhang, Jingjing Li, Xingyu Cao, Yanli Zhao, Zhijie Wei, Deyan Liu, Min Xiong, Yue Lu, Jiarui Zhou, Ruijuan Sun, Peihua Lu
Journal: Blood (2020)
Non-invasive prenatal testing for aneuploidy screening
Authors: Rebecca Spencer, Hilary Hewitt, Laura McCarthy, Ruwan Wimalasundera, Pranav Pandya
Journal: BMJ (2020)

### What you need to know

A 36 year old woman attends her general practice at 8 weeks in her second pregnancy. She has heard there is a new blood test she can have which will test for chromosomal anomalies and wants to find out more. 

In many countries, screening for trisomies 21 (Down’s syndrome), 18 (Edward’s syndrome), and 13 (Patau’s syndrome) is offered as part of routine antenatal care. This can be performed from 11+2 to 14+1 weeks’ gestation using combined screening (nuchal translucency, pregnancy-associated plasma protein A (PAPP-A), human chorionic gonadotrophin β subunit (βHCG) and maternal age) or from 14+2 to 20+0 weeks using quadruple screening (βHCG, unconjugated oestriol, α-fetoprotein and inhibin A). About 3% of women will receive a “high chance of trisomy” result from one of these screening tests and are traditionally offered an invasive procedure to confirm the result—either chorionic villus sampling (from 11+2 weeks) or amniocentesis (from 15+0 weeks). The disadvantage of these invasive procedures is the procedure-related risk of miscarriage of about 0.3%.1 Non-invasive prenatal testing (NIPT) is a newer screening test with high detection rates and low false positive rates.

Whether or not a pregnant woman chooses to have aneuploidy screening, the first trimester ultrasound scan remains an important test for dating the pregnancy and diagnosing multiple pregnancy, missed miscarriage, and early …
Abstract PO-113: Molecular interplay between dormant bone marrow-resident tumor cells (BMRCs) and CTCs in breast cancer
Authors: Debasish Boral, Haowen N. Liu, S. Ray Kenney, Dario Marchetti
Journal: Cancer Research (2020)

Abstract Despite widespread knowledge that bone marrow-resident breast cancer cells (BMRCs) affect tumor progression, signaling mechanisms of BMRCs implicated in maintaining long-term dormancy have not been characterized. Further, there is no model of clinical dormancy that can comprehensively emulate the entire spectrum of heterogeneous clones of Circulating Tumor Cells (CTCs) present in cancer patients. To overcome these hurdles, we developed a new experimental model of clinical dormancy employing patient-isolated de novo CTCs and their injection in xenografts with subsequent tumor monitoring and CTC characterization (ex vivo CTCs). We hypothesized that significant distinctions exist between signaling pathways of bone marrow-homing vs metastasis-competent CTCs upon transplantation in xenografts. Comparative transcriptomic analyses of ex vivo vs de novo CTCs identified increased mTOR signaling – a critical pathway frequently dysregulated in breast cancer and implicated in cell survival and dormancy – with contrasting actions by its two complementary arms (mTORC2/mTORC1). Heightened mTORC2 downstream targets augmented quiescent CTCs (Ki67-/RBL2+ cells) in paired breast cancer tissues, along with high mTORC2 activity in solitary BMRCs and tissue-resident CTCs. Further, shRNA mediated knockdown of RICTOR, an essential component of mTORC2, augmented Ki67/PCNA biomarker expression and proliferation. Collectively, these findings suggest that the balance between mTORC1 vs mTORC2 signaling regulates CTC-associated mitotic and/or dormancy characteristics. Further elucidation of mTOR-mediated CTC dormancy will provide novel strategies for therapeutic interventions in patients having early-event metastatic seeding but yet to develop clinically-detectable overt metastasis. Citation Format: Debasish Boral, Haowen N. Liu, S. Ray Kenney, Dario Marchetti. Molecular interplay between dormant bone marrow-resident tumor cells (BMRCs) and CTCs in breast cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-113.